| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2026-008 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海润达医疗科技股份有限公司（以下简称"本公司"或"公司"）股票 （股票简称：润达医疗 股票代码：603108）于 2026 年 1 月 8 日、1 月 9 日、1 月 12 日连续三个交易日内日收盘价格涨幅偏离值累计超过 20%，属于股票交易 异常波动。 经本公司自查，并向本公司控股股东核实，不存在应披露而未披露的重 大信息。 一、股票交易异常波动的具体情况 二、公司关注并核实的相关情况 1、生产经营情况 经自查，公司目前生产经营正常，公司经营情况及内外部经营环境没有发生 重大变化。 2、重大事项情况 经公司自查，并向公司控股股东书面征询核实：不存在关于公司的应披露而 未披露的重大事项，包括但不限于重大 ...

上海润达医疗科技股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上第六届董事会第一次会议通知于2026年1月7日以邮件形式发出，会议于 2026年1月12日（星期一）下午1:00-2:00在上海市虹口区乍浦路89号星荟中心1 座8楼公司会议室以现场及通讯相结合的方式召开。会议应到董事11人，实到董 事11人（其中董事赵斌、姚沈杰、王晶晶、金盈、朱明伟因工作原因以通讯方式 参会），公司高级管理人员廖上林列席了会议。会议由公司董事长张诚栩先生主 持。 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议合 法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-007 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 同意聘任胡震宁先生、陆晓艳女士为公司副 ...

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

智通财经APP获悉，浙商证券发布研报称，AI医疗应用在国家战略与市场需求的共振下已迈入商业化落 地的快速阶段。该行认为AI制药核心价值在于大幅提升药物早研效率，看好国内多家AI制药平台服务 能力全球领先。AI制药的高需求将带来较大的落地验证实验及合作需求，建议关注已与AI制药平台有 战略合作的传统CRO公司。此外，早研效率大幅提升将快速传导至临床前、安评以及临床CRO需求。 浙商证券主要观点如下： 该行认为AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物 从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提 升。该行看好：1)国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智 能、晶泰科技、泓博医药、维亚生物、成都先导等;2)AI制药的高需求将带来较大的落地验证实验及合 作需求，建议关注已与AI制药平台有战略合作的传统CRO公司，关注皓元医药、美迪西、百诚医药、 阳光诺和、药石科技、药明康德等;3)早研效率大幅提升将快速传导至临床前、安评以及临床CRO需 求，建议关注昭衍新药、美迪西、益诺思、泰格 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical sector experienced a weekly return of 7.81%, outperforming the CSI 300 index by 5.03%, ranking 6th among 31 primary sub-industry indices. The medical services sub-sector had the highest weekly increase of 12.34% [3][15] - The report highlights the impact of recent events such as Elon Musk's announcement regarding Neuralink's product mass production in 2026, Arrowhead Pharmaceuticals' promising clinical data for its siRNA therapy ARO-INHBE, and OpenAI's launch of "ChatGPT health," which have driven the sector's performance. The report suggests that while the brain-computer interface theme may be at a short-term emotional peak, AI medical applications still have room for growth [3][14] - Continuous investment in innovative drugs and related assets in the CXO and upstream life sciences sectors is recommended [3][14] Summary by Sections 1. Market Performance - The pharmaceutical sector's monthly return was 4.87%, outperforming the CSI 300 index by 1.37%, ranking 18th among 31 primary sub-industry indices. The medical services sub-sector had the highest monthly increase of 12.19% [15][20] 2. AI Medical Applications - AI applications in healthcare include AI+medical testing, AI+medical large models, AI+imaging, AI+e-commerce/precision marketing, and AI+gene sequencing, with notable companies such as KingMed Diagnostics, Dian Diagnostics, and BGI Genomics leading in these areas [4][16] 3. CXO and Upstream Life Sciences - Key global CXO leaders to watch include WuXi AppTec, WuXi Biologics, and Kelun Pharmaceutical. Domestic clinical CRO leaders include Tigermed and PPD. The report also highlights resource-based CXOs and upstream life sciences companies [5][16] 4. High-end Medical Devices - The report suggests focusing on companies involved in robotic applications, pharmaceutical equipment, and consumer medical devices, as demand is gradually recovering [5][16] 5. Innovative Drugs - Investment opportunities are identified in small nucleic acids, ADCs, and IO dual/multi-antibodies, with specific companies recommended for each category [6][16]

Group 1 - The core point of the news is that RunDa Medical's stock price increased by 5.07% to 18.85 CNY per share, with a total market capitalization of 11.379 billion CNY [1] - RunDa Medical, established on January 6, 1999, specializes in providing in vitro diagnostic products and professional technical support to various medical laboratories through its comprehensive service system [1] - The company's main revenue sources are: reagents and other consumables (93.50%), instruments (3.70%), software development and services (2.67%), and others (0.14%) [1] Group 2 - Huaxi Fund has a significant holding in RunDa Medical, with the Huaxi Research Selected Mixed Fund A (020444) holding 172,800 shares, representing 5.28% of the fund's net value, making it the seventh-largest holding [2] - The fund has generated a floating profit of approximately 157,200 CNY today, with a total fund size of 51.9921 million CNY [2] - Year-to-date, the fund has achieved a return of 10.02%, ranking 555 out of 9012 in its category, and a one-year return of 16.66%, ranking 5721 out of 8157 [2]

Core Viewpoint - The integration of artificial intelligence (AI) with the manufacturing sector is accelerating, fundamentally transforming production models and economic structures, and is seen as a key driver for industrial upgrades [2]. Group 1: Policy Implementation - The Ministry of Industry and Information Technology, along with seven other departments, issued the "Implementation Opinions on the 'AI + Manufacturing' Special Action," aiming to promote the application of AI in manufacturing and enhance new productive forces [2]. - The document outlines 21 specific measures across seven key areas, including innovation, intelligence upgrades, product breakthroughs, and international cooperation, with clear targets set for 2027 [2][3]. - Goals include launching 1,000 high-level industrial intelligent systems, creating 100 high-quality data sets, and promoting 500 typical application scenarios [2]. Group 2: Industry Empowerment - The initiative encourages deep engagement with key manufacturing sectors such as raw materials, equipment manufacturing, and consumer goods through expert-led service teams [3]. - It aims to customize AI products and solutions based on the characteristics of different countries and regions, while also attracting foreign investment into the AI sector [3]. Group 3: Operational Guidelines - Accompanying the main policy document, two attachments were released: the "Guidelines for AI Empowerment in Key Manufacturing Industry Transformation" and the "AI Application Guide for Manufacturing Enterprises," providing detailed operational instructions [4]. - These documents offer tailored transformation paths for five major industries and address common challenges faced by enterprises in adopting AI technologies [4]. Group 4: Potential for Upgrading - AI is rapidly integrating with the real economy, showcasing significant potential for "intelligent upgrades," as evidenced by successful applications in quality inspection processes [5]. - The drive for digital transformation in industries like non-ferrous metals is leading to improved production efficiency and energy effectiveness, with a focus on creating a shared AI empowerment system across all sectors [5]. Group 5: Strategic Insights - Experts highlight that despite advancements in AI and other technologies, China still lags behind developed countries, necessitating stronger government guidance and increased market participation to enhance technological innovation [6]. - The comprehensive policy framework aims to facilitate the intelligent upgrade of the manufacturing sector, thereby fostering new productive forces [6].

Group 1 - OpenAI has launched ChatGPT Health, a dedicated health assistant that allows users to connect personal medical records and health applications for tailored responses [1][2] - Over 230 million people globally consult ChatGPT for health-related inquiries each week, indicating strong demand for AI health tools [1][2] - ChatGPT Health features a separate storage mechanism to ensure health conversations and data are isolated from other chat records, emphasizing its role as an auxiliary tool rather than a diagnostic or treatment solution [1][2] Group 2 - Users can securely connect various data sources, including electronic health records and mainstream health apps, enabling personalized health insights based on individual health data [2] - The introduction of ChatGPT Health reflects the deepening penetration of AI into personal health management, potentially alleviating some pressure on healthcare systems [2] - The global AI healthcare market is projected to approach $40 billion by 2025 and exceed $500 billion by 2032, with a compound annual growth rate of over 40% [3] Group 3 - The launch of ChatGPT Health aligns with the trend of integrating fragmented health data into a single conversational interface, lowering the barrier to information access [3] - Major Chinese tech companies are rapidly entering the AI health sector, with various products competing for user attention [3] - The capital market reacted positively to the AI health sector, with significant stock price increases for companies involved in AI healthcare applications [4]

Investment Rating - The report indicates a stable investment outlook for the Shanghai real estate market, with a focus on the resilience of the TMT sector and emerging consumer trends [4][14]. Core Insights - The Shanghai office market saw a net absorption of approximately 390,000 square meters in 2025, a year-on-year increase of 76.6%, driven primarily by the TMT sector, which accounted for 20% of the demand [7][14]. - The retail market experienced a total net absorption of 678,000 square meters, with fashion and outdoor brands leading the growth, while the logistics sector achieved a historical high in net absorption at 1.07 million square meters [17][26]. - The investment market showed signs of recovery with 97 transactions recorded, totaling 47.4 billion RMB, despite a year-on-year decline in transaction volume and value [43][49]. Office Market Summary - In 2025, the Shanghai office market recorded 11 new projects with a total area of 792,000 square meters, but the overall pre-leasing rate was below 10%, leading to a vacancy rate increase of 1.2 percentage points to 23.3% [7][9]. - The TMT sector surpassed the financial industry in demand, with significant contributions from gaming, e-commerce, and AI companies [7][10]. - Major districts such as Lujiazui and Wujiaochang showed strong demand, with Lujiazui accounting for 7.8% of the market share [8][11]. Retail Market Summary - The retail market saw 708,000 square meters of new supply, with fashion apparel driving 43.4% of the demand, particularly from outdoor and Korean brands [17][18]. - The dining sector maintained a steady demand, accounting for 21% of the market, with a notable rise in health-oriented food options [18][19]. - The market is expected to see over 1.29 million square meters of new supply in 2026, driven by policies promoting smart experiences and health consumption [22]. Logistics Market Summary - The logistics market continued its high supply trend with 9 new projects totaling 899,000 square meters, despite a 43% year-on-year decrease in new supply [26]. - Net absorption reached a historical high of 1.07 million square meters, primarily driven by e-commerce and third-party logistics [26][27]. - The average rental price in the logistics sector decreased by 17.3% to 1.19 RMB per square meter per day [28]. Investment Market Summary - The investment market recorded a total of 97 transactions in 2025, with a total value of 47.4 billion RMB, reflecting a 26% year-on-year decline [43][49]. - Institutional investors led the market with a 40% share of transaction value, focusing on both office and rental residential assets [44]. - The market is transitioning towards a more refined focus on asset quality, with the introduction of commercial real estate REITs enhancing liquidity [49].

Market Performance - The pharmaceutical commercial sector increased by 1.32% on January 9, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers - RunDa Medical (603108) closed at 17.94, up 9.99% with a trading volume of 846,200 shares [1] - Huaren Health (301408) closed at 22.17, up 9.97% with a trading volume of 627,800 shares [1] - Shangyu Pingmin (301017) closed at 17.24, up 7.75% with a trading volume of 336,500 shares [1] Other Notable Stocks - Zhongyao Holdings (000950) closed at 6.31, up 5.87% with a trading volume of 1,147,000 shares [1] - Saily Medical (603716) closed at 27.83, up 4.39% with a trading volume of 783,100 shares [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 122 million yuan from institutional investors and 174 million yuan from speculative funds, while retail investors saw a net inflow of 296 million yuan [2] - The trading volume and turnover for various stocks indicate a mixed sentiment among different investor categories [2] Individual Stock Fund Flow - RunDa Medical had a net inflow of 2.30 billion yuan from institutional investors, while it faced a net outflow of 1.36 billion yuan from speculative funds [3] - Zhongyao Holdings saw a net inflow of 61.04 million yuan from institutional investors, with a net outflow of 62.93 million yuan from retail investors [3] - The overall fund flow indicates varying levels of confidence among different investor types in the pharmaceutical sector [3]